Helus Pharma Inc. (HELP) income statement
HELPNasdaqPharmaceutical PreparationsFiscal year ends March 31
$6.89−0.31 (-4.31%)
Close on Nov 18, 2026Market cap $355.74MP/E –Yield –
Helus Pharma Inc. financial ratios
See a number that looks wrong?
Close on Nov 18, 2026Market cap $355.74MP/E –Yield –
See a number that looks wrong?
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Margins | |||||||
| Gross margin | – | – | – | – | – | 23.1% | – |
| Free cash flow margin | – | – | – | – | – | -2,217.8% | – |
| Cash flow quality | |||||||
| OCF / Sales | – | – | – | – | – | -2,202.2% | – |
| FCF / OCF | – | – | 100.0% | 100.3% | 100.2% | 100.7% | – |
| Unlevered free cash flow | – | – | -68.93M | -47.57M | -45.31M | -19.16M | – |
| Levered free cash flow | – | – | -68.93M | -47.57M | -45.31M | -19.16M | – |
| Efficiency | |||||||
| Asset turnover | – | – | – | – | 0.00 | 0.01 | – |
| Fixed asset turnover | – | – | – | – | 0.00 | 1.55 | – |
| Receivables turnover | – | – | – | – | 0.00 | 0.65 | – |
| Days sales outstanding | – | – | – | – | – | 561.4 | – |
| Payables turnover | – | – | – | – | 0.00 | – | – |
| CapEx to revenue | – | – | – | – | – | 15.6% | – |
| CapEx to OCF | – | – | -0.03% | -0.30% | -0.23% | -0.71% | – |
| CapEx to depreciation | – | – | 0.05 | 0.57 | – | – | – |
| Liquidity | |||||||
| Current ratio | – | 7.75 | 21.65 | 4.09 | 7.38 | 13.57 | – |
| Quick ratio | – | 7.75 | 21.65 | 4.09 | 7.38 | 13.57 | – |
| Cash ratio | – | 6.30 | 20.70 | 2.94 | 6.78 | 13.07 | – |
| Working capital | – | 144.55M | 208.44M | 17.52M | 50.45M | 61.58M | – |
| Net current asset value | – | 144.55M | 208.44M | 17.52M | 50.45M | 60.49M | – |
| Leverage | |||||||
| Assets to equity | – | 1.09 | 1.03 | 1.12 | 1.10 | 1.07 | – |
| Goodwill / Assets | – | 19.9% | 15.7% | 46.0% | 27.2% | 25.4% | – |
| Intangibles to total assets | – | 35.8% | 27.5% | 56.1% | 29.7% | 27.2% | – |
| Per share | |||||||
| Revenue per share | – | – | – | – | 0.00 | 0.33 | – |
| EPS (basic) | – | -5.59 | -9.41 | -9.88 | -15.20 | -12.16 | – |
| EPS (diluted) | – | – | – | -9.88 | -15.20 | -12.16 | – |
| Book value per share | – | 11.73 | 35.18 | 9.88 | 17.30 | 32.72 | – |
| Tangible book value per share | – | 7.16 | 25.19 | 3.68 | 11.63 | 23.20 | – |
| Cash per share | – | 6.68 | 25.19 | 3.41 | 12.18 | 24.33 | – |
| Operating cash flow per share | – | -5.01 | -8.30 | -9.72 | -10.27 | -7.23 | – |
| Free cash flow per share | – | – | -8.31 | -9.75 | -10.29 | -7.28 | – |
| CapEx per share | – | – | 0.0025 | 0.03 | 0.02 | 0.05 | – |
| Valuation at period end | |||||||
| Market cap | 97.07M | 52.61M | 76.77M | 64.41M | 81.71M | – | – |
| Enterprise value | 298.81K | -92.74M | 64.47M | 24.74M | 30.41M | – | – |
| P/B | – | 0.2x | 0.3x | 1.3x | 1.1x | – | – |
| P/TBV | – | 0.4x | 0.4x | 3.6x | 1.6x | – | – |
| P/OCF | – | -0.5x | -1.1x | -1.4x | -1.8x | – | – |
| EV/OCF | – | 0.9x | -0.9x | -0.5x | -0.7x | – | – |
| FCF yield | – | – | -89.8% | -73.9% | -55.5% | – | – |
| Cost structure | |||||||
| R&D to revenue | – | – | – | – | – | 381.9% | – |
| Stock-based comp to revenue | – | – | – | – | – | 1,337.3% | – |
| Growth | |||||||
| Revenue 1Y growth | – | – | – | – | -100.0% | – | – |
| Gross profit 1Y growth | – | – | – | – | -100.0% | – | – |
| Diluted EPS 1Y growth | – | – | – | 35.0% | -25.0% | – | – |
| Operating cash flow 1Y growth | – | -47.0% | -45.3% | -4.9% | -137.6% | – | – |
| Free cash flow 1Y growth | – | – | -44.9% | -5.0% | -136.5% | – | – |
| CapEx 1Y growth | – | – | -85.2% | 35.2% | -22.2% | – | – |
| CapEx 3Y CAGR | – | – | -46.2% | – | – | – | – |
| Total assets 1Y growth | – | -14.4% | 460.4% | -35.9% | -8.7% | – | – |
| Total assets 3Y CAGR | – | 45.4% | 48.6% | – | – | – | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.